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Article Information  ABSTRACT 
Received: 11th December 2015  Dendrimers are highly branched, organic compounds with well-defined, symmetrical structure. 
From chemical point of view they are three-dimensional polymers, characterized by a globular 
shape. At the end of the arms are terminals, functional groups, which can be easily modified in 
order to change their chemical and physical properties. Dendrimers have nanoscopic particle 
size range from 1 to 100 nm. They are ideal drug delivery systems due to their feasible 
topology, functionality and dimensions, their size is very close to various important biological 
polymers and assemblies such as DNA and proteins. The structure of dendrimer molecules 
begins with a central atom or group of atoms labeled as the ―core.‖ From this central structure, 
branches of other atoms called ‗dendrons.‘ The continuous branching results in layers of branch 
structure called ―generations.‖Synthesis of dendrimers done by four methods. These are 
‗Divergent‘ Dendrimer Growth , ‗Convergent‘ Dendrimer Growth ,‗Double Exponential‘ and 
‗Mixed‘ Growth ,‗Click‘ Synthesis (Hypercores and branched monomers growth). Mechanisms 
of drug loading onto dendrimer carriers by physical encapsulation of drug molecules and 
chemical conjugation of drug molecules. The conjugates show increased solubility, decreased 
systemic toxicity and selective accumulation in solid tumors. Various applications as 
pharmaceutical and non pharmaceuticals. Dendrimers may have toxicity mainly attributed to the 
interaction of the cationic dendrimers surface with negative biological load membranes 
damaging cellular membranes causing hemolytic toxicity and cytotoxicity also limitation that 
does not apply where the drug is solubilised with dendrimer and then released in the gut for 
absorption. Some Marketed products of dendrimers are available named as Starburst, Priostar, 
Stratus CS, Vivagel, Alert ticket, SuperFect, Taxotere. 
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INTRODUCTION 
Dendrimers are highly branched, organic compounds with 
well-defined, symmetrical structure. From chemical point of 
view they are three-dimensional polymers, characterized by a 
globular shape. At the end of the arms are terminals, functional 
groups, which can be easily modified in order to change their 
chemical and physical properties. There are two types of 
dendrimer generation – a full generation with hydroxyl or 
amine surface group and a half generation with carboxyl 
surface group. The last characteristic elements in the structure 
of dendrimers are internal cavities – the empty spaces, which 
can be used as a ―pocket‖ for different kind of small particles1. 
Fig.1 Schematic description of dendrimer structure 
Dendrimers have often been referred to as the ―Polymers of the 
21st century‖. The word ―dendrimer‖ originated from two 
words, the Greek word Dendron, meaning tree, and meros, 
meaning part (Fig.1). At the same time, Newkome‘s group, 
independently reported synthesis of similar macromolecules. 
JOURNAL OF APPLIED PHARMACEUTICAL RESEARCH 
ISSN No. 2348 – 0335                                                                            www.japtronline.com 
Chaudhari et. al
 
Dendrimers: novel carriers for drug delivery 
 
 
Journal of Applied Pharmaceutical Research  January – March 2016  Volume 4 Issue 1  2 
They called them arborols from the Latin word ‗arbor‘ also 
meaning a tree. The term cascade molecule is also used, but 
‗dendrimer‘ is the best established one2. 
Advantages of Dendrimers 
Dendrimers offers various advantages over other polymers: 
a. Dendrimers have nanoscopic particle size range from 1 to 
100 nm, which makes them less susceptible for RES uptake.  
b. Due to stringent control during synthesis, they have lower 
polydispersity index. As the density of branches increases 
the outer most branches arrange themselves in the form of 
spheres surrounding a lower density core and outer surface 
density is more and most of the space remains hollow 
towards core. This region can be utilized for drug 
entrapment.  
c. Outer surface of dendrimers has multiple functional groups, 
which can be used to attach vector devices for targeting to 
particular site in the body.  
d. Dendrimers can be modified as stimuli responsive to release 
drug.  
e. Dendrimers might show an enhanced permeability and 
retention effect (depending on their M.W) that allows them 
to target tumor cells more effectively than small molecules.  
f. The advantage of dendrimers is that they can be synthesized 
and designed for specific applications. They are ideal drug 
delivery systems due to their feasible topology, 
functionality and dimensions; and also, their size is very 
close to various important biological polymers and 
assemblies such as DNA and proteins which are 
physiologically ideal.  
g. Medication to the affected part inside a patient's body 
directly.  
h. In target drug delivery: Dendrimers are suitable for 
targeting solid tumours due to increased permeability, 
limited drainage in tumour vasculature which will lead to 
accumulation of macromolecules in tumour (enhanced 
permeation rate). There is also reduction in amount of drug 
multiple acids. These two kinds of surfaces provide the 
means of attachment of multiple different functional 
components3-5. 
 
History of dendrimers 
During the 20th century, at least six major technological 
movements emerged and evolved into mature disciplines that 
have revolutionized scientific thinking, enhanced the prosperity 
of many countries, and dramatically improved the human 
condition. They have been referred to as major technological 
ages and, in approximate chronological order, are recognized as 
the chemical, nuclear, plastics, materials, biotechnology, and 
computer ages. An apparent driving force behind each 
technological age has been the quest for ―new properties‖.  
 
Table 1. Early Peer-Reviewed Publications on Dendritic 
Molecules (1978–1991) 
Year Lead Authors Working 
1978 Voegtle PAMAM dendrimers with 
molecular weights ranging from 
several hundred to over 1 million 
daltons (i.e., generations 1–13) were 
prepared in high yields.  
1983 de Gennes Predicted fundamental dendrimer 
surface congestion properties 
1985-
1990 
Newkome/ 
Baker 
initial presentation of convergently 
grown dendrimers was made 
1985-
1990 
Tomalia/ 
Turro/ Goddard 
There was an enormous amount of 
intrinsic interest in dendritic 
polymer architecture. 
1990-
1991 
Fre´chet/ 
Hawker 
Demonstrated the versatility of the 
convergent method with the 
preparation of dendrimers having 
differentiated functionalities6-20. 
1990 Miller/ Neenan 
random hyper 
branched 
polymers 
The convergent synthesis of an 
aromatic polyester was reported. 
1990 Kim/ Webster The rate of publication of dendrimer 
articles began to climb markedly 
while there were still only three 
articles on random hyper branched 
polymers. 
1991 Tomalia Articles on dendrigraft polymers. 
1991 Gauthier/ 
Mo¨ller 
Articles on Arborescent polymers. 
 
Properties of dendrimers 
1. Dendritic polymers that can be constructed with a well-
defined molecular structure, i.e. being mono-disperse, 
unlike to linear polymers.  
2. Nanoscale sizes that have similar dimensions to important 
bio-building blocks, e.g., proteins, DNA. 
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3. When dendrimer surfaces modified with small functional 
groups or polyethylene glycol (PEG) show non or low 
immunogenicity. 
4. Ability to arrange excretion mode from body, as a function 
of nanoscale diameter.  
5. An interior void space may be used to encapsulate small 
molecule drugs, metals, or imaging moieties, reduces the 
drug toxicity and facilitates controlled release.  
6. Numbers of terminal surface groups suitable for 
bioconjugation of drugs, signalling groups, targeting 
moieties or biocompatibility groups.  
7. Surfaces that may be designed with functional groups to 
resist trans-cellular, epithelial or vascular bio permeability.  
8. Dendrimers are monodisperse macromolecules. Size and 
molecular mass of dendrimers can be specifically 
controlled during classical polymerization process.  
9. When the molecular mass of dendrimers increases, their 
intrinsic viscosity goes through a maximum at the fourth 
generation and then begins to decline.  
10. The presence of many chain-ends is responsible for high 
solubility and miscibility and for high reactivity.  
11. Dendrimer solubility is strongly influenced by the nature 
of surface groups.  
12. The dendrimer should be: nontoxic, on-immunogenic, able 
to cross bio barriers (biopermeable), able to stay in 
circulation for the time needed to have a clinical effect and 
able to target to specific structures21 , 22.  
 
Fig. 2 Representation of the four major classes of 
macromolecular architectures 
 
TYPES OF DENDRIMERS 
Physical type of dendrimers 
a) PAMAM Dendrimer  
Poly (amidoamine) dendrimers (PAMAM) are synthesized by 
the divergent method starting from ammonia or 
ethylenediamine initiator core reagents. Starburst dendrimers is 
applied as a trademark name for a sub-class of PAMAM 
dendrimers based on a tris-aminoethylene-imine core.  
b) PAMAMOS Dendrimers  
Poly(amidoamine-organosilicon) dendrimers (PAMAMOS) are 
inverted unimolecular micelles that consist of hydrophilic, 
nucleophilic polyamidoamine (PAMAM) interiors and 
hydrophobic organosilicon (OS) exteriors. These dendrimers 
are exceptionally useful precursors for the preparation of honey 
comb like networks with nanoscopic PAMAM & OS domain.  
c) PPI Dendrimer  
PPI-dendrimers stand for ―Poly (Propylene Imine)‖ PPI 
dendrimers are commercially available up to G5, and has found 
widespread applications in material science as well as in 
biology. As an alternative name to PPI, POPAM is sometimes 
used to describe this class of dendrimers. POPAM stands for 
Poly (Propylene Amine).  
d) Tecto Dendrimer  
These are composed of a core dendrimer, surrounded by 
dendrimers of several steps (each type design) to perform a 
function necessary for a smart therapeutic nanodevice 
Multilingual Dendrimers In these dendrimers, the surface 
contains multiple copies of a particular functional group.  
e) Chiral Dendrimers  
The chirality in these dendrimers are based upon the 
construction of a constitutionally different but chemically 
similar branches to chiral core.  
f) Hybrid Dendrimers Linear Polymers  
These are hybrids (block or graft polymers) of dendritic and 
linear polymers.  
g) Amphiphilic Dendrimers  
They are built with two segregated sites of chain end, one half 
is electron donating and the other half is electron withdrawing.  
h) Micellar Dendrimers  
These are unimolecular micelles of water soluble hyper 
branched polyphenylenes.  
 
i) Multiple Antigen Peptide Dendrimers  
It is a dendron-like molecular construct based upon a 
polylysine skeleton. Lysine with its alkyl amino side-chain 
serves as a good monomer for the introduction of numerous of 
branching points. This type of dendrimer was introduced by J. 
P. Tam in 1988, has predominantly found its use in biological 
applications, e.g. vaccine and diagnostic research. 
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j) Frechet-Type Dendrimers  
It is a more recent type of dendrimer developed by Hawker and 
Frechet based on poly-benzyl ether hyper branched skeleton. 
These dendrimers usually have carboxylic acid groups as 
surface groups, serving as a good anchoring point for further 
surface functionalisation, and as polar surface groups to 
increase the solubility of this hydrophobic dendrimer type in 
polar solvents or aqueous media23-27. 
 
Fig. 3 Dimensionally scaled comparison of series of PAMAM 
dendrimers (NH3 core; G 4–7) with a variety of proteins, a 
typical lipid-bilayer membrane & DNA, indicating closely 
matched size & contours of important proteins & bioassemblies 
 
Chemical types of dendrimers 
1. Simple Dendrimer 
They have simple monomer units. Convergent synthesis of 
sequence of monodisperse are lester dendrimer, based upon 
symmetrically substituted benzene tricarboxylic acid ester is 
described. These materials consist of 4, 10, 22 & 46 benzene 
rings linked symmetrically & have molecular diameters of 
45A. 
2. Liquid crystalline dendrimer  
These are made of mesogenic monomers e.g. mesogen 
functionalized carbosilane dendrimer. 
3. Chiral dendrimer 
Chirality is based on the building of 4 constitutionally assorted 
but chemically alike branches to an achiral core e.g. chiral 
dendrimers obtained from pentaerythritol 
4. Micellar dendrimer  
These are unimolecular micelle arrangement dendrimers. Fully 
aromatic, water soluble dendrimers forming a collection of 
aromatic polymeric chain which able to generate an 
environment that resembles some micellar structures, which 
forms complex with small organic molecules in water. 
5. Hybrid dendrimers  
These are the preparation of dendritic and linear polymer in 
hybrid block or graft copolymer form. e.g. hybrid dendritic 
linear polymers. 
6. Amphiphilic dendrimer  
These are the class of globular dendrimers that have 
asymmetrical but highly controlled division of chain end 
chemistry. These may be oriented at interface forming 
interfacial liquid membranes for neutralizing aqueous organic 
emulsion  
7. Metallo dendrimer  
Dendrimers attached with the metal ion to form the 
complexation either in the interior or on the peripheral, which 
may be regarded as metallodendrimers. The ruthenium 
bipyridine complex based dendrimer have attribute 
electrochemical and luminescence properties28. 
 
Table. 2 Properties of dendrimers 
Property  Dendrimers  Linear Polymers  
Structure  Compact, 
Globular  
Not compact  
Synthesis  Careful & 
stepwise growth  
Single step 
polycondensation  
Structural 
control  
Very high  Low  
Architecture  Regular  Irregular  
Shape  Spherical  Random coil  
Crystallanity  Non-crystalline, 
amorphous 
materials -lower 
glass temp. 
Semicrystalline/crystalline 
materials -Higher glass 
temperatures  
Aqueous 
solubility  
High  Low  
Non-polar 
solubility  
High  Low  
Viscosity  Nonlinear 
relationship 
with molecular 
weight  
Linear relation with 
molecular weight  
Reactivity  High  Low  
Compressibility Low  High  
Polydispersity  Monodisperse  Polydisperse  
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STRUCTURE OF DENDRIMERIC MOLECULE 
The structure of dendrimer molecules begins with a central 
atom or group of atoms labeled as the core. From this central 
structure, branches of other atoms called ‗dendrons‘ grow 
through various chemical reactions. The continuous branching 
results in layers of branch structure called ―generations.‖ 
Another way to determine the generation of a dendrimer is 
through the total number of focal or branching points (from the 
core to the surface) that it has. For example, a dendrimer with 4 
focal points would be a fourth generation dendrimer, labeled as 
G4. There is a myriad of generations, ranging from just a few 
to hundreds or even thousands. As the molecule grows bigger, 
the structure becomes denser and more tightly packed. 
Eventually, the branches cannot grow any further because there 
is no room. The generation at which this occurs is different for 
every molecule, but it is known as the starburst effect. The 
shape of lower generation molecules (such as G0, G1, and G2), 
tend to be asymmetrical, but as the generation number 
increases, the structure becomes more spherical. Other 
components of dendrimers include the shell (segment between 
focal points), and the end-group (the atoms that make up the 
surface of the molecule).  
Fig. 4 
Generations of Dendrimers 
Dendrimers are built from a starting atom, such as nitrogen, to 
which carbon and other elements are added by a repeating 
series of chemical reactions that produce a spherical branching 
structure. As the process repeats, successive layers are added 
and the sphere can be expanded to the desired size by the 
investigator. The final entity is spherical macromolecular 
structure whose size is similar to blood albumin and 
hemoglobin.  
 
In PPI and PAMAM dendrimers the number of pincers is half 
the number of surface groups (because in these dendrimers the 
chain divides into two chains in each focal point ). End group is 
also generally referred to as the ―terminal group‖ or the 
―surface group‖ of the dendrimer. Dendrimers having amine 
end-groups are termed ―aminoterminated dendrimers‖.       
 
Fig. 5 Three dimensional projection of dendrimer core-shell 
architecture for G=4.5 PAMAM dendrimer with principal 
architectural components (I) core, (II) interior & (III) surface.  
 
Fig. 6 (A) 2D Representation of dendrimers demonstrating its 
different components (B) 3D Representation of dendrimers 
 
Fig. 7 PAMAM dendrimer crystal structure of 1st generation 
polyphenylene dendrimer. 
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COMPONENTS OF DENDRIMERS 
a. Generation  
It is the hyper branching going from the centre of the 
dendrimer towards the periphery, resulting in homostructural 
layers between the focal points (branching points). The number 
of focal points going from the core towards the dendrimer 
surface is the generation number.  
 
Dendrimer having five focal points when going from the centre 
to the periphery is denoted as the 5th generation dendrimer and 
abbreviated as G5-dendrimer, e.g. a 5th generation 
polypropylene imine is abbreviated to a ―G5-PPI‖ dendrimer. 
The core part of the dendrimer is sometimes denoted as 
generation ―zero‖, or in terminology as ―G0‖. The core 
structure thus presents no focal points as hydrogen substituent‘s 
are not considered focal points. Intermediates during the 
dendrimer synthesis are sometimes denoted as half-generations; 
a well-known example is the carboxylic acid-terminated 29 , 30 
 
b. Shell  
The dendrimer shell is the homostructural spatial segment 
between the focal points. The ―outer shell‖ is the space 
between the last outer branching point and the surface. The 
―inner shells‖ are generally referred as the dendrimer interior.  
 
 
Fig. 8 Structure of Poly propylene amine 
c. Pincer  
In dendrimer, the outer shell consists of a varying number of 
pincers created by the last focal point before reaching the 
dendrimer surface. In PPI and PAMAM dendrimer the number 
of pincers is half the number of surface groups (because in 
these dendrimers chain divides into two in each focal point).  
 
d. End-group  
It is also generally referred to as the ―terminal group‖ or the 
―surface group‖ of the dendrimer. Dendrimers having amine 
end-groups are termed ―amino-terminated dendrimers‖. 
 
SYNTHESIS of dendrimers 
‘Divergent’ Dendrimer Growth  
This name comes from the way in which the dendrimer grows 
outwards from the core, diverging into space. Divergently 
grown dendrimers are virtually impossible to isolate pure from 
their side products. The first synthesized dendrimers were 
polyamidoamines (PAMAMs). Divergent synthesis is initiated 
with a multifunctional core molecule like ethylenediamine 
(EDA), then with the help of Michael addition reaction four 
arms are added on nitrogen of EDA (two arms possible on each 
nitrogen), after this in second step EDA is again reacted on 
these formed four arms through amidation reaction as shown in 
following diagram These two steps can be repeated multiple 
times to formdifferent generations of dendrimers, in each 
generation number of arms doubles from previous generation.  
 
To avoid structural defects at higher generations a large excess 
of Michael donor (EDA) is used in this approach. This 
divergent route is advantageous to get higher yield ofdendrimer 
with lower purity or we can say that purity is compromised for 
getting higher yield. That‘s why this approach of synthesis is 
very useful and used worldwideat commercial scale for 
production of dendrimers. Lesser purity in divergent synthesis 
of dendrimers. Lesser purity in divergent synthesis of 
dendrimers is basically due to missing repeat units  
Fig. 9 Synthesis by Divergent method 
‘Convergent’ Dendrimer Growth 
The 'convergent' approach was developed as a response to the 
weaknesses of divergent syntheses. Convergent growth begins 
at what will end up being the surface of the dendrimer, and 
works inwards by gradually linking surface units together with 
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more. The advantages of convergent growth over divergent 
growth stem that only two simultaneous reactions are required 
for any generation-adding step.  
a. Relatively easy to purify the desired product and the 
occurrence of defects in the final structure is minimised.  
b. Possible to introduce subtle engineering into the dendritic 
structure by precise placement of functional groups at the 
periphery of the macromolecules.  
c. Approach does not allow the formation of high generation 
dendrimer because stearic problems occur in the reactions of 
the dendrons and the core molecule. 
d. Convergent approach of dendrimer synthesis overcomes the 
purity and structural defect issues of divergent synthesis. By 
this approach more uniform and symmetric dendrimers can be 
synthesized but with lower overall yield. In other words yield is 
sacrificed for purity and this approach is generally used for 
laboratory scale dendrimer synthesis. For commercial scale 
production, divergent synthesis is still favored. Most 
commonly used commercially available dendrimers are 
PAMAM and PPI, which are structurally somewhat different in 
every batch due to structural defects.  
e. Convergent approach of dendrimer synthesis was first 
introduced by Jean Frechet. In this approach dendrons that ends 
up to terminal groups are synthesized first and in final step 
these are linked together to a core molecule for getting 
complete dendrimer structure as shown in figure10. 
Dendrimers synthesized by this way have less impurities, more 
monodispersity and symmetry because better purification is 
possible of dendrons before final attachment to core.  
 
Fig. 10 Synthesis by Convergent method 
 
Fig. 11 Divergent & convergent method of dendrimer synthesis 
 
 
 
Fig. 12 Divergent & convergent method of dendrimer synthesis 
 
‘Double Exponential’ And ‘Mixed’ Growth 
The most recent fundamental breakthrough in the practice of 
dendrimers synthesis has come with the concept and 
implications of 'double exponential' growth. A schematic 
representation of double exponential and mixed growth. This 
approach allows the preparation of monomers for both 
convergent and divergent growth froma single starting material. 
These two products are reacted together to give an orthogonally 
protected trimer, which may be used to repeat the growth 
process again31. 
 
Fig. 13 Double exponential growth 
‘Click’ Synthesis 
 ―Click‖ chemistry refers to Cu-catalyzed cycloaddition 
reaction of an alkyne and an azide to form a 1,2,3-triazole ring. 
The coupling specificity, mild reaction conditions, and 
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quantitative synthetic yields of click reactions motivated the 
synthesis of dendrimers using this method.G3 triazole 
dendrimers were synthesized using a branched alkyne 
monomer with an alkyl chloride focal point.Using the 
convergent approach, dendrons are synthesized by triazole 
formation with the peripheral monomer alkynes followed by 
conversion of the focal point to an azide functionality for 
reiterative monomer addition (Figure 14). Coupling of the 
dendrons to a polyacetylene core produced G3 triazole 
dendrimers with a 92% yield after simple aqueous workup and 
filtration to remove the NaCl byproduct. It is important to note 
that ―clicked‖ dendrons can be used to produce symmetricand 
asymmetric PAMAM This method involved the pre-assembly 
of oligomeric species which can be linked organic 
methodologies. 32-36 
 
Fig. 14 Hypercores and branched monomers growth 
 
MECHANISMS OF DRUG LOADING ONTO 
DENDRIMER CARRIERS 
Physical Encapsulation of Drug Molecules 
The work of Vogtle and co-workers, who looked at entrapment 
of guest molecules into branched polymers,1 represents an 
earlier form of physical encapsulation of poorly soluble drug 
molecules in dendrimer‘s voids to improve their aqueous 
solubility and control their release profile Inclusion of 
hydrophobic molecules into dendrimers is typically 
accomplished by simple mixing of the polymer and drug 
solutions where the hydrophobic drug associates with the 
nonpolar core through hydrophobic intereactions. As a result of 
this physical interface between the guest molecules and the 
dendrimer carrier, release of the encapsulated molecules in an 
aqueous environment is passively controlled by a range of 
noncovalent interactions including hydrophobic forces, 
hydrogen bonding, steric hindrance, and electrostatic 
interactions. To maximize the loading capacity of drug 
molecules within the dendrimer, one has to carefully consider 
polymer architecture, specifically the characteristics of the 
internal voids. Initial computational and experimental studies 
by Goddard and Tomalia showed that G1-G3 -alanine 
dendrimers exhibit an oblong open structure while G4 and 
higher generations possess a densely packed surface that is 
necessary to produce enclosed internal voids that can 
effectively encapsulate and retain guest molecules. Spin-lattice 
relaxation profiles of acetyl salicyclic acid and 2,4-
dichlorophenoxy acetic acid encapsulated within a dendritic 
carrier displayed a decline in carbon-13 relaxation time with 
increasing dendrimer‘s generation number from G0.5-G5.5, 
thus indicating the shielding of the guest molecules in the 
polymer network. These findings set the stage for development 
of different inclusion complexes where dendrimers can 
encapsulate hydrophobic anticancer drugs to improve their 
aqueous solubility, control their release rates, and achieve 
cancer therapy. 
 
Fig. 15 Drawing of a dendrimer carrier encapsulating 
hydrophobic drug molecules in the dendrimer‘s voids to 
increase their aqueous solubility and control their release rate           
 
Fig. 16 Schematic drawing showing a Dendrimer drug 
conjugate where the drug molecules (red ovals)           are either 
directly coupled (solid lines) dendrimer‘s surface groups or via 
pH sensitive linkage (blue rectangle) 
 
The well defined 3D structure and many functional surface 
groups, drug molecules can be loaded both in the interior of the 
dendrimers as well as attached to the surface groups ( as shown 
in the figure). Dendrimers can function as drug carriers either 
by encapsulating drugs within the dendritic structure, or by 
inter-acting with drugs at their terminal functional groups via 
electrostatic or covalent bonds (prodrug).37-39 
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There are broadly two mechanisms for drug delivery :- 
A) First, is by in vivo degradation of drug dendrimer conjugate 
(covalent bonding of drug to dendrimer), which depends on 
presence of suitable enzymes or an environment capable of 
degrading bonds.  
B) The second one is by releasing the drug due to changes in 
physical environment such as pH, temperature. This approach 
is independent of the external factors and takes place in cavities 
of the core (endo-receptor) or outer shell of receptor (exo-
receptor).40 
 
Chemical Conjugation of Drug Molecules 
a. Direct Coupling 
In the early 1990s, Barth and co-workers conjugated boronated 
monoclonal antibodies to a dendrimer carrier via stable urea 
linkages and utilized this conjugate for neutron capture therapy 
where localized neutron ionization would cause necrosis of 
neighboring cancer cells.113,139 This conjugate achieved high 
loading capacities of 250-1000 boron atoms per G4 dendrimer 
while retaining 82% of the antibodies activity in vitro. A few 
years later, Duncan and coworkers reported the coupling of 
cisplatin (Pt), a hydrophobic DNA intercalating agent, to G3.5 
PAMAM dendrimers via an ester linkage.140 PAMAM-Pt 
conjugates carried 20-25 weight % platinum exhibiting 10-fold 
higher aqueous solubility compared to free Pt and displayed 
great stability (<1% Pt release) upon incubation in PBS (pH 
7.4) and citrate buffers (pH 5.5) at 37 °C for 72 h.140 Despite 
the high aqueous solubility and stability of these conjugates, 
they failed to produce the desired anticancer activity due to 
limited drug release.  
 
b. pH-Sensitive Linkages 
The desire to achieve cancer cell-specific delivery and release 
of anticancer drugs motivated the development of dendrimer-
drug conjugates with hydrolyzable linkages. Specifically, the 
sought linkages had to remain intact in the systemic circulation 
but quickly degrade once internalized into the cancer cell and 
release the attached drug to produce the desired therapeutic 
activity. The incorporation of pH sensitive linkages into 
dendrimer-drug conjugates seemed to fit the desired criteria as 
they remain stable in the systemic circulation (pH 7.4) but 
quickly hydrolyze in acidic environment (pH 5-6) like the 
endosomes/lysosomes, thus releasing the incorporated drug 
inside the target cell. While these pH-sensitive linkages 
represent a significant improvement over non cleavable 
conjugates for intracellular drug delivery of anticancer drugs, 
they only sense the acidity of the endosomal compartment but 
fail to differentiate between cancer cells and normal healthy 
ones.  
Therefore, further selectivity of drug release from dendrimer 
conjugates can be achieved by development of novel chemical 
linkages that are sensitive to cancer-specific markers such as 
intracellular enzymes.41-48 
 
CHARACTERIZATION OF DENDRITIC POLYMER 
A. Spectroscopy and spectrometry methods:-Spectroscopy 
and spectrometry methods of characterization of dendritic 
polymer are as follows. 
a. Ultra-violet-visible spectroscopy(UV-VIS):-Provides 
information for monitoring the synthesis of dendrimers. The 
intensity of the absorption band is basically proportional to 
the number of chromophoric units. 
b. Infra red spectroscopy (IR):-Provides information for 
routine analysis of the chemical transformations going at 
the surface of dendrimers. 
c. Near infra red spectroscopy:-Provides information for the 
characterization of delocalize π-π stacking interaction 
between end groups of modified PAMAM. 
d. Fluorescence:-Provides information for increasingly high 
Sensitivity of fluorescence used to quantify defects during 
the synthesis of dendrimers. 
e. Mass spectroscopy:-Chemical ionization or fast atom 
bombardment used for the characterization of small 
dendrimers whose mass is below 3000Da. Electrospray 
ionization used for dendrimers which are able to form stable 
multicharged species. 
f. X-ray diffraction (XRD):-Provides information to allow 
precise determination of the chemical composition, 
structure, size and shape of Dendrimer. 
Fig. 19 
Dendrimer 
molecule with 
drug molecules 
encapsulated   
Fig. 18 Dendrimer 
molecule with 
drug molecules 
loaded within 
branches 
Fig. 17 
Structure of  
Dendrimer at 
terminal surface 
of branches 
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B. Scattering techniques:-Scattering techniques for 
characterization of dendritic polymer are as follows  
a. Small angle X-ray scattering (SAXS):-Provides information 
about their average radius of gyration (Rg) in solution. The 
intensity of the scattering also provides information on the 
arrangement of polymer segments. 
b. Small angle neutron scattering (SANS):-Provides access to 
the radius of gyration, but may also disclose more accurate 
information than SAXS. The location of the ending groups 
has also been determined by SANS experiments conducted 
with PAMAM dendrimers and PPI dendrimers. 
c. Laser light scattering (LLS):-It determines the 
hydrodynamic radius of dendrimers. Dynamic LLS is 
mostly used for the detection of aggregates. 
 
C. Microscopy methods:- Microscopy methods for 
characterization of dendritic polymer are,  
a. Transmission microscopy:-Electron or light produce images 
that intensify the original, with a resolution eventually 
limited by the wavelength of the source. 
b. Scanning microscopy:-It produces an image by touch 
contact Q at a few angstroms of a sensitive canilever arm 
with sample. Ex. Atomic force microscopy. 
 
D. Size exclusive chromatography:- It allows the partition of 
molecules according to size.37 
 
E. Electrical techniques:- Electrical techniques for 
characterization of dendritic polymer are as follows  
a. Electron paramagnetic resonance (EPR):-Quantitative 
determination of the substitution effectiveness on the 
surface of PANAM dendrimers. 
b. Electrochemistry:-It provides information about the 
possibility of interaction of electroactive end groups. 
c. Electrophoresis:-It provides the information about the 
assessment of purity and homogeneity of several types of 
water soluble dendrimers. 
 
F. Rheology and Physical properties:- Rheology and physical 
properties used for characterization of dendritic polymer are as 
follows  
a. Intrinsic viscosity:-It is as analytical probe of the 
morphological structure of dendrimers. 
b. Differential scanning calorimetry (DSC):- It used to detect 
the glass transition temperature depends on thy moleculer 
weight, entangment and chain composition of polymers. 
c. Dielectric spectroscopy (DS):- Gives complete information 
about molecular dynamic processes (α-, β) 
 
G. Miscellaneous methods:- Other methods used of 
characterization of dendritic polymer are as follows  
a. X-ray Photoelectron Spectroscopy (XPS):-It provides 
detailed information about chemical composition of 
dendrimers such as poly (aryl ether) dendrons or PAMAM 
dendrimers which was obtained using XPS. This technique 
is most generally used for the characterization of layers. 
b. Sedimentation Technique:- Used for lactosylated PAMAM 
dendrimers, measurements of dipole moments for PMMH 
dendrimer. 
c. Titrimetry:-It is used for determining number of NH2 end 
groups of PAMAM dendrimers.49-68 
 
APPLICATIONS of dendrimers 
A. Non-Pharmaceutical Application: 
1. Diagnostics 
2. Dendritic Catalysts / Enzymes 
3. Industrial Processes 
B. Pharmaceutical Application: 
1. Covalent Dendrimer–Drug Conjugates 
2. Noncovalent Encapsulation of Drugs / Host –Guest 
3. Delivery of Anticancer Drugs by Dendrimers and Dendritic 
Polymers 
4. Dendrimers Drug Delivery: Targeted and Controlled 
Release Drug Delivery 
5. Dendrimer as Solubility Enhancers 
6. Dendrimers in Photodynamic Therapy 
7. Dendrimers as Nano-Drugs 
C. Miscellaneous Applications of The Dendrimers  
D. Current And Potential Applications Of Dendrimers:  
A. Non-Pharmaceutical Application  
1. Diagnostics  
Paramagnetic metal chelates such as Gd(III)- 
N,N‘,N‘‘,N‖‘tetracarboxymethyl-1,4,7,10-tetraazacy-
clododecane (Gd(III)DOTA), Gd(III)-diethylene tri- amine 
pentaacetic acid (Gd(III)DTPA), and their derivatives used as 
contrast agents for magnetic resonance imaging(MRI). DNA-
dendrimers, which are constructed for routine, use in high-
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throughput functional genomics analysis, and as biosensors for 
the rapid diagnosis have genetic, and pathogenesis diseases. 
 
2. Dendritic Catalysts / Enzymes  
The combination of high surface area and high solubility makes 
dendrimers useful as nanoscale catalysts. Dendrimers have a 
multifunctional surface and all catalytic sites are always 
exposed towards the reaction mixture. 
a) Metallodendritic catalysts. 
b) Catalysis with phosphine-based dendrimers.  
c) Catalysis with (metallo) dendrimers containing chiral 
ligands.  
d) Non-metal containing dendrimers.69-84 
 
3. Industrial Processes  
Dendrimers can encapsulate insoluble materials, such as 
metals, and transport them into a solvent within their interior. 
Cooper and co-workers synthesized fluorinated dendrimers, 
which are soluble in supercritical CO2 and can be used to 
extract strongly hydrophilic compounds from water into liquid 
CO2. 
 
B. Pharmaceutical Application: 
1. Covalent Dendrimer–Drug Conjugates  
An alternative approach to the development of dendrimers as 
anticancer drug carriers is to exploit their well-defined 
multivalency for the covalent attachment of drug molecules to 
the dendrimers periphery. In dendrimer–drug conjugates, the 
drug is attached through a covalent bond either directly or via a 
linker/spacer to the surface groups of a dendrimer. Dendrimers 
have been conjugated to various biologically active molecules 
such as drugs, antibodies, sugar moieties and lipids. Conjugates 
of PAMAM dendrimers with cisplatin, a potent anticancer drug 
with non-specific toxicity and poor water solubility. The 
conjugates show increased solubility, decreased systemic 
toxicity and selective accumulation in solid tumors. 
 
2. Non covalent encapsulation of drugs/Host-guest relation  
Encapsulation of drugs use the satiric bulk of the exterior of the 
dendrimer or Interactions between the dendrimer and drug to 
trap the drug inside the dendrimer. Maciejewski introduced the 
concept of encapsulating guest molecules into special, egg-
shell-like structures. Such a system can be used to encapsulate 
drugs and provide controlled delivery. For example, in early 
studies, DNA was complexed with PAMAM dendrimers for 
gene delivery applications. 
 
3. Delivery of Anticancer Drugs by Dendrimers and 
Dendritic Polymers 
 Dendrimer molecule has hundreds of possible sites to couple 
to an active species. This might allow researchers to attach both 
targeting molecules and drug molecules to the same dendrimer, 
which could reduce negative side effects of medications on 
healthy cells. Poly(amidoamine) (PAMAM) dendrimers are 
emerging as prospective candidates for efficient targeted drug 
and peptide delivery system due to their hyperbranched, 
welldefined globular nanometer-sized, multiple end modifiable 
groups and high biocompatibility. PAMAM dendrimers have 
been used for drug delivery platform, by covalently 
conjugating drug molecules for cancer therapeutics. 
Conjugation of poor-bioavailable drugs with PAMAM 
dendrimer increases their bioavailability, and decreases dose 
frequency. Methotrexate (MTX) conjugated with dendrimer 
showed 8-fold more toxic effect against resistant human acute 
lymphoblastoid, as compared to free MTX. It has also been 
reported that tamoxifen conjugated to PAMAM dendrimer 
enhances the blood brain barrier (BBB) transportation and 
improves the drug accumulation in glioma cells. The covalent 
attachment of drugs on to dendrimer surfaces offers stable 
dendrimer-drug conjugates. It is necessary to cleave the 
covalent attachment between drug and dendrimer in order to 
optimize drug release at the specific biological condition. The 
covalent linkage of the drugs to the surface functional groups 
of dendrimer can be achieved via ester or amide or disulphide 
bond, which can be cleaved hydrolytically or enzymatically or 
via glutathione. 85-92 
 
4. Dendrimers Drug Delivery: Targeted And Controlled 
Release Drug Delivery  
Dendrimers have attracted attention as possible drug carriers 
because of their unique properties namely their well defined 
three dimensional structure, the availability of many functional 
surface groups, their low polydispersity and their ability to 
mimic. Drug molecules can be loaded both in the interior of the 
dendrimers as well as attached to the surface groups. 
Dendrimers can function as drug carriers either by 
encapsulating drugs within the dendritic structure, or by inter-
acting with drugs at their terminal functional groups via 
electrostatic or covalent bonds (prodrug). 
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Fig. 20 Cancer targeted drug delivery 
a) Dendrimers for controlled release drug delivery 
The anticancer drugs adriamycin and methotrexate were 
encapsulated into PAMAM dendrimers (i.e. G=3 and 4) which 
had been modified with PEG monomethyl ether chains (i.e. 550 
and 2000 Da respectively) attached to their surfaces. drug gives 
slow and sustained in vitro release, as compared to cellulose 
membrane control. Controlled release of the Flurbiprofen could 
be achieved by formation of complex with amine terminated 
generation 4 (G4) PAMAM Dendrimers  
  
b) Dendrimers in targeted drug delivery  
Dendrimers have ideal properties which arebrought in 
application in targeted drug delivery system. One of the most 
effective cell-specific targetingagents delivered by dendrimers 
is folic acid PAMAM dendrimers modified with 
carboxymethyl PEG5000 surface chains possessed reasonable 
drug loading, a reduced release rate and reduced haemolytic 
toxicity compared with the non-PEGylated dendrimer. The star 
polymer were reported to give the most promising results 
regarding cytotoxicity and systemic circulatory half-life (72 h). 
In addition to improving drug properties such as solubility and 
plasma circulation time polymeric carriers can also facilitate 
the passive targeting of drugs to solid tumours. Combined these 
factors lead to the selective accumulation of macromolecules in 
tumour tissue, a phenomenon termed the ‗Enhanced 
Permeation and Retention‘ (EPR) effect. Therefore, the 
anticancer drug doxorubicin was reported to be covalently 
bound to this carrier via an acid-labile hydrazone linkage. The 
cytotoxicity of doxorubicin was significantly reduced (80–
98%), and the drug was successfully taken up by several cancer 
cell lines. 
 
c) Dendrimers in Gene Transfection(For Gene Delivery ) 
The ability to deliver pieces of DNA to required parts of a cell 
involves many challenges. Research is being performed to find 
ways to use dendrimers to traffic genes into cells without 
damaging or deactivating the DNA. To maintain the activity of 
DNA during dehydration, the dendrimer-DNA complexes are 
encapsulated in a water soluble polymer, and then deposited on 
or sandwiched in functional polymer films with a fast 
degradation rate to mediate gene transfection.93 Based on this 
method, PAMAM dendrimer-DNA complexes were used to 
encapsulate functional biodegradable polymer films for 
substrate mediated gene delivery. Dendrimers can act as 
vectors, in gene therapy. PAMAM dendrimers have been 
tested as genetic material carriers. Numerous reports have been 
published describing the use of amino-terminated PAMAM or 
PPI dendrimers as non-viral gene transfer agents, enhancing the 
transfection of DNA by endocytosis and, ultimately, into the 
cell nucleus. A transfection reagent called SuperFectTM 
consisting of activated dendrimers is commercially available. 
 
Fig. 21 Gene delivery by dendrimer 
 
d) For nanoparticles encapsulation 
Dendrimers are also used in the synthesis of mono disperse 
metallic nanoparticles. Poly(amidoamide), or PAMAM, 
dendrimers are utilized for their tertiary amine groups at the 
branching points within the dendrimer. Metal ions are 
introduced to an aqueous dendrimer solution and the metal ions 
form a complex with the lone pair of electrons present at the 
tertiary amines. After complexion, the ions are reduced to their 
zerovalent states to form a nanoparticle that is encapsulated 
within the dendrimer.  
 
e) In Sensor Technology  
Scientists have also studied dendrimers for use in sensor 
technologies. Studied systems include proton or pH sensors 
using cadmium- sulfide- polypropylenimine tetrahexaconta 
amine dendrimer composites to detect fluorescence signal 
quenching, and poly(propylenamine) first and second 
Chaudhari et. al
 
Dendrimers: novel carriers for drug delivery 
 
 
Journal of Applied Pharmaceutical Research  January – March 2016  Volume 4 Issue 1  13 
generation dendrimers for metal cation photo detection 
amongst others. Research in this field is vast and ongoing due 
to the potential for multiple detection and binding sites in 
dendritic structures94.  
 
f) Blood Substitution  
Dendrimers are also being investigated for use as blood 
substitutes. Their steric bulk surrounding a heme-mimetic 
centre significantly slows degradation compared to free heme 
and prevents the cytotoxicity exhibited by free heme.95, 96 
 
g) As Drug Carriers in Sexually Transmitted Diseases  
Dendrimers as Nano-Drug carriers are useful against the herpes 
simplex virus as it can potentially prevent or reduce 
transmission of HIV and other sexually transmitted diseases 
(STDs), when drug delivery is made through Poly(lysine) 
dendrimers modified with sulfonated naphthyl groups.97 
 
h) Dendrimer in Ocular Drug Delivery  
PAMAM dendrimers with carboxylic or hydroxyl surface 
groups, have been reported in improving residence time and 
enhancing bioavailability of pilocarpine in the eye.98 
 
i) Dendrimers in Pulmonary Drug Delivery  
Positively charged PAMAM dendrimers (G2 and G3 
generation) increased the relative bioavailability of pulmonary 
drug delivery of Enoxaparin.99 
 
j) Dendrimer in transdermal drug delivery  
Dendrimers has been found improve solubility and plasma 
circulation time via transdermal and to deliver drugs 
efficiently. PAMAM dendrimer complex with NSAIDs (e.g. 
Ketoprofen, Diflunisal) have been reported to improve the drug 
permeation through the as penetration enhancers. Ketoprofen 
and Diflunisal were with G5 PAMAM dendrimer and showed 
3.4 and 3.2 times higher permeation. Enhanced bioavailability 
of PAMAM dendrimers by using indomethacin as the model 
drug in transdermal drug application was to be effective. 
 
k) Dendrimer in oral drug delivery  
Oral drug delivery studies the colon adenocarcinoma cell line, 
Caco2, have indicated that low generation PAMAM 
dendrimers cross cell membranes, presumably through a 
combination of two processes, i.e. paracellular transport and 
adsorptive endocytosis. Remarkably, the P-glycoprotein efflux 
transporter does not appear to affect dendrimers, therefore drug 
dendrimer complexes are able to bypass the efflux transporter. 
PAMAM dendrimers conjugated with the folic acid and 
fluorescein isothiocyanate for targeting the tumor cells and 
imaging respectively.  
 
l) Dendrimer hydrogel for ocular drug delivery  
Dendrimers are especially ideal for synthesizing hydrogels, 
cross-linked networks that increase in volume in aqueous 
solution and are more similar to living tissue than any other 
synthetic compound. By adding polyethylene glycol or PEG 
groups to the dendrimers, these hydrogels have applications 
including cartilage tissue production and for sealing ophthalmic 
injuries. By synthesizing a hydrogel composed of PEGylated 
dendrimers that contain ocular drug molecules attached to the 
dendrimers efficiently deliver the drugs to the eye. 
  
m) Cellular Delivery Using Dendrimer Carriers  
Dendrimer–ibuprofen complexes entered the cells rapidly 
compared with pure drug (1 hr versus>3 hr), suggesting that 
dendrimers can efficiently carry the complexed drug inside 
cells.PAMAM dendrimers were surface-engineered with lauryl 
chains to reduce toxicity and enhance cellular uptake. 
  
5. Dendrimer as Solubility Enhancers  
There are many substances, which have a strong therapeutic 
activity but due to their lack of solubility in pharmaceutically 
acceptable solvents have not been used for therapeutic 
purposes. Water soluble dendrimers are capable of binding and 
solubilizing small acidic hydrophobic molecules with 
antifungal or antibacterial properties. Dendrimers having a 
hydrophobic core and a hydrophilic surface layer, have been 
termed unimolecular micelles. A hydrophilic–hydrophobic 
core-shell dendrimer with PAMAM interior and long alkane 
chain exterior was shown to bind 5-flurouracil, a water-soluble 
anti-tumor drug. Dendrimers have unimolecular miceller 
nature, due to hydrophilic exterior and hydrophobic interiors it 
forms covalent as well as non covalent complexes with drug 
molecules and hydrophobes and enhance its solubility 
behaviour.  
 
6. Dendrimers In Photodynamic Therapy 
 The photosensitizer 5-aminolevulinic acid has been attached to 
the surface of dendrimers and studied as an agent for PDT of 
tumorigenic keratinocytes. Photosensitive dyes have been 
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incorporated into dendrimers and utilized in PDT devices. This 
cancer treatment involves the administration of a light- 
activated photosensitizing drug that selectively concentrates in 
diseased tissue. 
 
 7. Dendrimers as Nano-Drugs  
Poly(lysine) dendrimers modified with sulfonated naphthyl 
groups have been found to be useful as antiviral drugs against 
the herpes simplex virus can potentially prevent/reduce 
transmission of HIV and other sexually transmitted diseases 
(STDs). Chitosan– dendrimer hybrids have been found to be 
useful as antibacterial agents, carriers in drug delivery systems, 
and in other biomedical applications 
 
C. Miscellaneous Applications of The Dendrimers  
 Delivery of nucleic acids.  
 Film-forming agents for controlled release.  
 Lubricants for pharmaceutical processing and 
engineering.  
Dendrimers typically involve conjugating other chemical 
species to the dendrimer surface that can function as detecting 
agents (such as a dye molecule), affinity ligands targeting 
components, radio ligands, imaging agents, or 
pharmaceutically active compounds.  
 
D. Current and Potential Applications of Dendrimers:  
 Delivery of Nucleic acids, Encapsulated drugs and 
Covalently linked drugs. 
 Film-forming agents for controlled release. 
 Lubricants for pharmaceutical processing and engineering. 
 New carrier system for drug delivery (gels, self-associating 
systems) 
 Vaccines against bacteria, viruses and parasites. 
 Modification of cell-cell interactions and gene expression 
(e.g.: alteration of transcription factors binding to DNA) 
 Diagnostic reagents in: serodiagnosis (systems with 
surface ligands), Biosensor systems (systems containing 
dyes, reactive molecules) magnetic resonance imaging 
(e.g.: gadolinium adducts). 
 Dendrimers typically involve conjugating other chemical 
species to the dendrimer surface that can function as 
detecting agents (such as a dye molecule), affinity ligands, 
targeting components, radio ligands, imaging agents, or 
pharmaceutically active compounds 
Today, dendrimers have many medicinal and practical 
applications. Firstly, they are used in cardiac testing. In this 
method, proteins from a blood sample are attached to glass by 
dendrimers. The result tells if there is any muscle damage, and 
significantly reduces the testing time from 40 minutes to 8. 
Dendrimers are also used as contrast agents in MRIs (Magnetic 
resonance imaging). Contrast agents improve sensitivity and 
specificity during the imaging process. One dendrimer 
molecule has hundreds of possible sites to couple to an active 
species. This might allow researchers to attach both targeting 
molecules and drug molecules to the same dendrimer, which 
could reduce negative side effects of medications on healthy 
cells. 
 
CYTOTOXICITY ISSUES REPORTED IN VIVO 
a. Dendrimers with positively charged surface groups prone 
to destabilize cell membranes and cause cell lysis.  
b. Generation dependent toxicity-higher generation 
dendrimers being the most toxic.  
c. Degree of substitution, type of amine functionality is 
important- primary amines being more toxic than 
secondary or tertiary amines 
 
 Toxicity and Pegylation:-  
It is known that the dendrimers may have toxicity mainly 
attributed to the interaction of the cationic dendrimers surface 
with negative biological load membranes damaging cellular 
membranes causing hemolytic toxicity and cytotoxicity. 
Therefore, PAMAM dendrimers are more cationic than anionic 
cytotoxic. An example of interaction with lipid bilayers of cells 
occurs with the cationic dendrimer-G7 PAMAM which comes 
to form holes 15-40 nm in diameter, which disturbs the flow of 
electrolyte causing cell death. Many toxic effects of dendrimers 
are attenuated at their surfaces with hydrophilic molecules and 
poly (ethylene glycol) (PEG) which masks the surface charge 
cationic dendrimers improving biocompatibility and increasing 
the solubility of the polymers. The pegylated dendrimers have 
lower cytotoxicity and longer stay in the blood than non-
pegylated dendrimers. PEGylation increases the physical 
dendrimers size which reduces renal clearance. 
 
Limitations of dendrimers 
 An intact dendrimer-drug construct does not generally cross 
the gut wall and so the approach may not be a good choice 
for certain oral administration applications. Obviously this 
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limitation does not apply where the drug is solublised with 
dendrimer and then released in the gut for absorption.  
 The drug-dendrimer construct will generally be considered 
to be a New Chemical Entity (NCE), meaning that clinical 
testing of the new construct may be required. This is 
normally not seen as an issue for preclinical drugs, which 
will require full clinical testing anyway, but the approach 
may require review before application to a candidate 
already in the clinic. Helpfully, the construct may be 
considered to be a prodrug allowing bridging data from 
previous studies to be used.  
 
MARKETED PRODUCTS AVAILABLE  
Table. 4 Marketed products of dendrimers 
Product Company Utilization 
Starburst Dow chemical Targeted diagnostic and 
therapeutic delivery 
Priostar Starpharma For cancer. 
Stratus CS Dade Behring Cardiac marker 
Vivagel Starpharma Vaginal Gel for 
Prevention of HIV 
infection 
Alert ticket US Army 
Research Lab. 
Anthrax detection 
SuperFect Qiagen Gene transfection 
Taxotere Sanofi Aventis Anticancer drug 
delivery100 
        
CONCLUSION 
Dendrimer drug delivery is in its infancy, it offers several 
attractive features. This novel class of polymers and their 
derivatives exhibit unique physicochemical and biological 
properties, which have great potential for use in variety of 
applications. It has greater flexibility in design.High control 
over branching length ,shape and size allows modification 
according to delivery system, so these serves as ideal carrier for 
drug and other application. The main purpose of this review is 
to focus various valuable applications of dendrimer . We still 
do not know whether these synthetic polymer, once they 
entered the body can cause damage to other tissue. Even 
though toxicity problem if arise, that will be minimized by 
modifying dendrimer architecture. As the system involves 
multistep process future work is necessary to find out cost 
effective synthesis strategies. 
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